The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Eligibility
- Age range
- 35–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Hemoglobin A1C between 5.7 and 6.4 * Body mass index between 27 and 45 Exclusion Criteria: * Diabetes * Chronic use of any antidiabetic medications * Any unstable medical condition * Use of steroids or daily use of NSAIDS * History of chronic inflammatory conditions * Use of anticoagulants * Contraindications to the use of mirabegron or tadalafil * Any condition deemed risky by the study physician
Interventions
- DrugMirabegron 50 MG
Mirabegron 50 mg/day will be administered for 14 weeks.
- DrugTadalafil 10 MG
Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
- DrugPlacebo
Placebo will be administered for 14 weeks after baseline procedures.
Location
- University of KentuckyLexington, Kentucky